Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with <i>MYD88</i> L265P mutation

• Ivan Dlouhy,
• Marc Armengol,
• Clara Recasens-Zorzo,
• Marcelo L Ribeiro,
• Patricia Pérez-Galán,
• Francesc Bosch,
• Armando López-Guillermo,
• Gaël Roué

Affiliations

Ivan Dlouhy

Department of Hematology, Hospital Clínic, BarceIona, Spain; Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona

Marc Armengol

Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain; Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona

Clara Recasens-Zorzo

Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona

Marcelo L Ribeiro

Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain; Post Graduate Program in Health Science, Universidade São Francisco (USF), Bragança Paulista, Brazil

Patricia Pérez-Galán

Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona

Francesc Bosch

Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona

Armando López-Guillermo

Department of Hematology, Hospital Clínic, BarceIona, Spain; Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona

Gaël Roué

Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona